Intelligent Bio 2025 Q4 Earnings Mixed Results with Narrowed Losses

Intelligent Bio (INBS) reported its fiscal 2025 Q4 earnings on Aug 15th, 2025. The company posted a revenue increase of 52.4% year-over-year, but its losses remained a key concern. The results show signs of operational improvements but highlight continued financial challenges.

Intelligent Bio reported total revenue of $1.23 million in 2025 Q4, representing a 52.4% increase from $805,683 in the same period in 2024. While this reflects strong top-line growth, the company has yet to turn a profit. The earnings report also noted that Intelligent Bio narrowed its per-share loss to $0.42 from $0.81 a year earlier, an improvement of 47.6%. However, its net loss widened to $-3.10 million in 2025 Q4, up 11.0% from $-2.80 million in the prior-year quarter. The company has posted losses in the same quarter for six consecutive years, underscoring the ongoing financial challenges it faces.

The company’s stock price has seen significant declines in recent periods, with a 0.68% drop in the latest trading day and a 3.29% decline over the past week. The month-to-date drop has been even more pronounced at 30.99%. Historically, a strategy of buying INBS shares following its earnings release and holding for 30 days has resulted in no return over the past three years. This has led to a compound annual growth rate (CAGR) of 0.00%, a negative excess return of -64.97%, and a Sharpe ratio of 0.00%, suggesting no volatility in the stock. The benchmark return during the same period was 64.97%.

Harry Simeonidis, President and CEO of Intelligent Bio Solutions, described the year as pivotal, with sequential revenue growth, operational improvements, and regulatory progress. He highlighted the company's focus on cartridge sales, international expansion, and advancing its FDA clearance for broader U.S. market entry. Looking ahead, the CEO outlined strategic priorities, including accelerating growth, enhancing operational excellence, and expanding into new U.S. markets. He expressed confidence in the regulatory pathway and emphasized the company’s commitment to offering a non-invasive drug screening solution in the U.S.

The company remains focused on driving new active account growth and advancing its FDA 510(k) clearance for its opiate test system. It is also pursuing regulatory expansion in Canada, Indonesia, and the Philippines. INBS aims to strengthen its business fundamentals through localized strategies and continued growth in key international markets such as the UK, Europe, and the Middle East.

Additional News
In recent news from Nigeria, Punch Newspapers reported on several significant developments. A flight attendant strike in Canada has caused travel disruptions, and political tensions continue to escalate in the region. By-election concerns are also rising, with political parties warning the Independent National Electoral Commission (INEC) against bias. Meanwhile, Nigeria is grappling with social issues such as illegal mining, sex trafficking, and rising crime rates. The country's political landscape remains turbulent, with allegations of election sabotage and calls for greater transparency in the electoral process.